Eli Lilly and Company (BVMF:LILY34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 5.38T +46.7% |
| Revenue (ttm) | 412.73B +49.6% |
| Net Income | 138.38B +93.6% |
| EPS | 154.33 +94.8% |
| Shares Out | n/a |
| PE Ratio | 38.89 |
| Forward PE | 30.07 |
| Dividend | 0.74 (0.37%) |
| Ex-Dividend Date | May 14, 2026 |
| Volume | 54,930 |
| Open | 205.03 |
| Previous Close | 203.08 |
| Day's Range | 197.60 - 205.03 |
| 52-Week Range | 113.00 - 214.47 |
| Beta | 0.51 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Broad Market Momentum & Defensive Pivots: This Week's Top ETF Flows
The ETF market saw a massive surge into core index heavyweights this past week, as investors poured billions into broad U.S. equities and mega-cap tech leadership. However, this aggressive accumulatio...
Eli Lilly price target raised to $1,376 from $1,370 at Truist
Truist raised the firm’s price target on Eli Lilly (LLY) to $1,376 from $1,370 and keeps a Buy rating on the shares. Eli Lilly delivered strong Q2 performance with substantial…
Eli Lilly (LLY) Stock Remains a Buy after Q2
Eli Lilly ($LLY) remains a Buy after another strong quarter, in my view. Shares of the Indiana-headquartered drugmaker have trailed the S&P 500 (SPX) in 2026 even as LLY posted…
Jim Cramer highlights 5 investing themes — and the stocks to buy for each
CNBC's Jim Cramer said earnings season reinforced five investing themes he thinks will produce the market's best buying opportunities. He highlighted stocks to buy for each theme, including Capital On...
3 Most Active ‘Strong Buy’ Stocks with Market-Topping Gains — August 6, 2026
Shopify ($SHOP), Booking ($BKNG), and Eli Lilly ($LLY) were among the most active and best-performing stocks on Wednesday. More importantly, all three companies currently carry a Strong Buy consensus ...
Rumors Swirl That Eli Lilly (LLY) Will Split Its Stock After Blockbuster Earnings
The pharma giant hasn’t split its shares since 1997.
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
Both Eli Lilly and Novo Nordisk beat second-quarter estimates and raised their full-year outlooks. But while investors cheered Lilly's results, they punished Novo a day earlier – underscoring a growin...
Eli Lilly price target raised to $1,410 from $1,350 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Eli Lilly (LLY) to $1,410 from $1,350 and keeps an Overweight rating on the shares. Eli Lilly delivered a strong Q2 with…
Eli Lilly price target raised to $1,419 from $1,347 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Eli Lilly (LLY) to $1,419 from $1,347 and keeps an Overweight rating on the shares. The firm views Lilly’s Q2 results and…
Eli Lilly price target raised to $1,400 from $1,300 at BMO Capital
BMO Capital analyst Evan Seigerman raised the firm’s price target on Eli Lilly (LLY) to $1,400 from $1,300 and keeps an Outperform rating on the shares. The company delivered a…
Eli Lilly price target raised to $1,330 from $1,280 at Wells Fargo
Wells Fargo analyst Mohit Bansal raised the firm’s price target on Eli Lilly (LLY) to $1,330 from $1,280 and keeps an Overweight rating on the shares. The firm believes the…
Wednesday's Final Takeaways: GOOGL AI Chief Leaves, GLP-1 Boosts LLY
Marley Kayden and Sam Vadas wrap up Wednesday's session with a few overlooked headlines to keep on the radar. Marley details a cautionary note from Bank of America (BAC) CEO Brian Moynihan before turn...
Market Close: Stock Rally Fades, Job Growth Weakens, Strong Earnings Boost Eli Lilly 8-5-2026
CNBC Business News Update with Peter Schacknow - Markets & Business News With Expert Analysis From Top Business Names. Visit CNBC.com For More.
Healthcare Stocks Have Been Forgotten. Eli Lilly, McKesson, and 9 More to Buy.
A few sectors have dominated the market this year, and healthcare isn't one of them. Many stocks in the sector look ready to gain.
Inside Out: LLY and the Future of Weight Loss Drugs
Matt Tuttle can't quite pronounce the name of Eli Lilly's (LLY) oral weight-loss drug, but that doesn't stop him from understanding its significance to the healthcare company's future. He reacts to th...
Eli Lilly stock surges 6% after Q2 earnings beat driven by Mounjaro, Zepbound
Eli Lilly stock LLY gained 6% on Wednesday after delivering a stronger-than-expected second quarter as robust demand for its blockbuster GLP-1 medicines Mounjaro and Zepbound lifted revenue and profit...
LLY Earnings: Eli Lilly’s Stock Jumps on Blowout Financial Results
The company continues to dominate the obesity drug market.
Eli Lilly and Company Earnings Call Transcript: Q2 2026
Q2 2026 saw 48% revenue growth year-over-year, driven by strong performance across all therapeutic areas and geographies, with key products like MOUNJARO and ZEPBOUND leading. Full-year guidance was raised, major regulatory and pipeline milestones were achieved, and access to obesity medicines expanded significantly.
Eli Lilly and Company Slides: Q2 2026
Eli Lilly and Company has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Eli Lilly and Company Earnings release: Q2 2026
Eli Lilly and Company released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Eli Lilly and Company Quarterly report: Q2 2026
Eli Lilly and Company has published its Q2 2026 quarterly earnings report on August 5, 2026.
Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand
Eli Lilly reported higher net income and revenue in the recent quarter, fueled by continued surging demand for its GLP-1 weight-loss drugs.
Eli Lilly narrows FY26 EPS view to $35.50-$36.50 from $35.50-$37.00
Consensus $34.54. Raises FY26 revenue view to $85B-$87B from $82B-$85B, consensus $85.15B. The company said, “The first half of 2026 also benefited from sales based milestones and adjustments for reba...
Lilly's revenue soars 48%, driven by demand of its GLP-1s
Its sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.
Eli Lilly reports Q2 EPS $8.38, consensus $6.58
Reports Q2 revenue $22.97B, consensus $20.69B. “Lilly’s momentum continues, as we delivered 48% revenue growth and raised our full-year guidance,” said David A. Ricks, Lilly chair and CEO. “At the…